Generic Patanol Availability
PATANOL (olopatadine hydrochloride - solution/drops; ophthalmic)
Approval date: December 18, 1996
Strength(s): EQ 0.1% BASE [RLD]
Has a generic version of Patanol been approved?
No. There is currently no therapeutically equivalent version of Patanol available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Patanol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Topical ophthalmic formulations for treating allergic eye diseases
Issued: June 24, 1997
Inventor(s): Hayakawa; Eiji & Nakakura; Masashi & Robertson; Stella M. & Yanni; John Michael
Assignee(s): Alcon Laboratories, Inc. Kyowa Hakko Kogyo Co. Ltd.
Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.Patent expiration dates:
- June 6, 2015✓
- December 6, 2015✓
- June 6, 2015
- Patanol Consumer Information (Drugs.com)
- Patanol drops Consumer Information (Wolters Kluwer)
- Patanol Consumer Information (Cerner Multum)
- Patanol Advanced Consumer Information (Micromedex)
- Patanol AHFS DI Monographs (ASHP)
- Olopatadine drops Consumer Information (Wolters Kluwer)
- Olopatadine ophthalmic Consumer Information (Cerner Multum)
- Olopatadine Ophthalmic Advanced Consumer Information (Micromedex)
- Olopatadine Hydrochloride AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|